Literature DB >> 2994223

Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene.

F D Veronese, A L DeVico, T D Copeland, S Oroszlan, R C Gallo, M G Sarngadharan.   

Abstract

Radiolabeled amino acid sequencing was used to characterize gp41, an antigen of HTLV-III/LAV, the virus believed to be the etiological agent of the acquired immune deficiency syndrome. This antigen is the one most commonly detected in immunoblot assays by sera of patients with AIDS or AIDS-related complex (ARC) and other individuals infected with HTLV-III/LAV. A mouse monoclonal antibody that was reactive with gp41 precipitated a 160-kilodalton protein (gp160) in addition to gp41, but did not precipitate a 120-kilodalton protein (gp120) from extracts of metabolically labeled cells producing HTLV-III. Extracts of infected cells that had been labeled with tritiated leucine or isoleucine were immunoprecipitated with the monoclonal antibody. The immunoprecipitates were fractionated by polyacrylamide gel electrophoresis and the p41 was eluted from the gel bands and subjected to amino-terminal radiolabeled amino acid sequencing by the semiautomated Edman degradation. Leucine residues occurred in cycles 7, 9, 12, 26, 33, and 34 among 40 cycles and isoleucine occurred in cycle 4 among 24 cycles analyzed. Comparison of the data with the deduced amino acid sequence of the env gene product of HTLV-III precisely placed gp41 in the COOH-terminal region of the env gene product. Gp160 is thus the primary env gene product and it is processed into gp120 and gp41.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2994223     DOI: 10.1126/science.2994223

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  140 in total

1.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.

Authors:  X Yang; L Florin; M Farzan; P Kolchinsky; P D Kwong; J Sodroski; R Wyatt
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Furin is involved in baculovirus envelope fusion protein activation.

Authors:  Marcel Westenberg; Hualin Wang; Wilfred F J IJkel; Rob W Goldbach; Just M Vlak; Douwe Zuidema
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Membrane structure of the human immunodeficiency virus gp41 fusion domain by molecular dynamics simulation.

Authors:  Shantaram Kamath; Tuck C Wong
Journal:  Biophys J       Date:  2002-07       Impact factor: 4.033

5.  Viral DNA carried by human immunodeficiency virus type 1 virions.

Authors:  F Lori; F di Marzo Veronese; A L de Vico; P Lusso; M S Reitz; R C Gallo
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

6.  Evaluation of an indirect immunofluorescence assay for confirmation of human immunodeficiency virus type 1 antibody in U.S. blood donor sera.

Authors:  M T Sullivan; H Mucke; S D Kadey; C T Fang; A E Williams
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

7.  A chimeric protein of simian immunodeficiency virus envelope glycoprotein gp140 and Escherichia coli aspartate transcarbamoylase.

Authors:  Bing Chen; Yifan Cheng; Lesley Calder; Stephen C Harrison; Ellis L Reinherz; John J Skehel; Don C Wiley
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1.

Authors:  W R Lee; W J Syu; B Du; M Matsuda; S Tan; A Wolf; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

9.  Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1.

Authors:  D C Montefiori; W E Robinson; W M Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

10.  Processing of the envelope glycoprotein gp160 in immunotoxin-resistant cell lines chronically infected with human immunodeficiency virus type 1.

Authors:  T D Duensing; H Fang; D W Dorward; S H Pincus
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.